FY2019 EPS Estimates for Charles River Laboratories Intl. Inc (NYSE:CRL) Decreased by Analyst

Charles River Laboratories Intl. Inc (NYSE:CRL) – Investment analysts at Jefferies Financial Group cut their FY2019 earnings estimates for shares of Charles River Laboratories Intl. in a research report issued on Monday, October 21st. Jefferies Financial Group analyst D. Windley now forecasts that the medical research company will post earnings per share of $6.46 for the year, down from their previous forecast of $6.47. Jefferies Financial Group also issued estimates for Charles River Laboratories Intl.’s Q2 2020 earnings at $1.77 EPS, Q4 2020 earnings at $2.08 EPS and FY2020 earnings at $7.32 EPS.

Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Wednesday, July 31st. The medical research company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.55 by $0.08. The company had revenue of $657.60 million during the quarter, compared to the consensus estimate of $662.61 million. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The company’s revenue was up 12.4% on a year-over-year basis. During the same period last year, the firm earned $1.62 earnings per share.

Other analysts also recently issued reports about the company. SunTrust Banks raised their target price on Charles River Laboratories Intl. from $156.00 to $162.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Credit Suisse Group set a $138.00 target price on Charles River Laboratories Intl. and gave the company a “hold” rating in a research note on Friday, September 13th. Zacks Investment Research downgraded Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Monday. Bank of America downgraded Charles River Laboratories Intl. from a “buy” rating to a “neutral” rating and set a $150.00 target price for the company. in a research note on Friday, October 18th. Finally, ValuEngine downgraded Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Seven research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $150.46.

Shares of Charles River Laboratories Intl. stock opened at $127.62 on Thursday. The business has a 50-day moving average of $132.86 and a 200-day moving average of $134.21. The company has a debt-to-equity ratio of 1.47, a current ratio of 1.59 and a quick ratio of 1.38. The company has a market capitalization of $6.17 billion, a PE ratio of 21.16, a P/E/G ratio of 1.94 and a beta of 1.09. Charles River Laboratories Intl. has a 1-year low of $103.00 and a 1-year high of $149.07.

In other news, insider David Ross Smith sold 1,249 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $130.36, for a total transaction of $162,819.64. Following the transaction, the insider now owns 19,327 shares of the company’s stock, valued at $2,519,467.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.80% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Squar Milner Financial Services LLC lifted its holdings in Charles River Laboratories Intl. by 253.2% in the third quarter. Squar Milner Financial Services LLC now owns 219 shares of the medical research company’s stock worth $28,000 after acquiring an additional 157 shares during the last quarter. Flagship Harbor Advisors LLC lifted its holdings in Charles River Laboratories Intl. by 132.1% in the second quarter. Flagship Harbor Advisors LLC now owns 318 shares of the medical research company’s stock worth $45,000 after acquiring an additional 181 shares during the last quarter. CWM LLC lifted its holdings in Charles River Laboratories Intl. by 75.9% in the third quarter. CWM LLC now owns 387 shares of the medical research company’s stock worth $51,000 after acquiring an additional 167 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new position in Charles River Laboratories Intl. in the second quarter worth about $69,000. Finally, Point72 Asset Management L.P. bought a new position in Charles River Laboratories Intl. in the second quarter worth about $71,000. 94.25% of the stock is currently owned by institutional investors and hedge funds.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: Do You Need a Fiduciary?

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.